AlphAIAlphAI — Financial news for AI agents
quiverquant.com$EXEL

Exelixis gains after Q3 beat and fresh price-target hike

Exelixis (EXEL) shares rose 4.8% after its Q3 earnings and revenue beat estimates, driven by strong CABOMETYX sales. The company repurchased $250M in stock and holds $1.4B in cash. Morgan Stanley raised its price target to $60 from $53, maintaining an Equalweight rating.

Original reporting
quiverquant.com
Published Oct 30, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 4:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Exelixis gains after Q3 beat and fresh price-target hike — source image
Source · quiverquant.com
Decision brief

The 30-second read

$EXELBullishHigh
01

Why it matters

The earnings surprise and target raise provide a clear short‑term bullish catalyst, though insider sales and recent hedge‑fund exits could add volatility.

02

Market read

The earnings beat and target hike are likely to drive immediate buying pressure, with potential spillover to other oncology biotech stocks.

03

What to watch

Large insider sell activity may temper enthusiasm despite the earnings beat.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction today

Background

Exelixis reported Q3 2026 results, beating expectations on EPS and revenue, with strong performance from its CABOMETYX franchise and a $250M share repurchase.

Company-level read

Ticker impact

$EXELBullishHigh confidence
Context

Q3 2026 earnings beat with EPS $0.94 and revenue $658.7M, plus a price‑target raise to $60, drove a 4.8% price gain.

Expected impact

upward pressure as the market prices in the earnings beat and higher target.

Evidence & confidence

Beat on both EPS and revenue, strong CABOMETYX sales, and a fresh $60 price target from Morgan Stanley create a clear bullish catalyst.

Market effects

Sector

Biotech sector may see modest rally as Exelixis' beat reinforces confidence in oncology pipelines.

Regional

U.S. market likely to open higher on biotech earnings strength.

Global

Limited to U.S. biotech investors; no broad macro effect.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Analyst
    Morgan Stanley

    Raised EXEL price target to $60 from $53.

Read at source← All news

StoryExelixis beats third-quarter estimates and maintains 2026 revenue guidance

Also covered by

3 outlets

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

finance.yahoo.com
$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

finance.yahoo.com
$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.

investing.com
$EXELMedAI 8/10

Exelixis beats Q3 estimates but stock edges lower on guidance

Exelixis (NASDAQ:EXEL) reported Q3 adjusted EPS of $0.94, beating estimates by $0.07, with revenues of $658.7M, up 10.2% YoY. FY2026 revenue guidance of $2.5B-$2.55B was maintained, slightly below analyst consensus. Shares fell 0.15% post-announcement. The company expects topline results from its phase 3 STELLAR-304 trial in Q1 2027 and updated its effective tax rate guidance to 16%-18%.

investing.com